Combined 177 Lu-FAP-2286 Therapy and Immunotherapy in Metastatic Esophageal Squamous Cell Carcinoma.

Clin Nucl MedJul 28, 2026 (epub)

Lixian Mou, Yemei Liu, Hongyu Yang et al.

✦ AI-curated · Sources linked

Case in brief

A 72-year-old man with low-to-moderate-grade esophageal squamous cell carcinoma, previously treated with surgery, radiotherapy, chemotherapy, and immunotherapy, presented with bilateral cervical lymph-node metastases. He was treated with two cycles of 177 Lu-FAP-2286 combined with camrelizumab. Follow-up imaging with 68 Ga-FAP-2286 PET/CT showed significant reduction of the metastatic lesions, and the treatment was well tolerated without severe adverse reactions.

Diagnostic / clinical pearl

This case highlights the potential of combining targeted radioligand therapy with immunotherapy in managing metastatic esophageal squamous cell carcinoma.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.